158 related articles for article (PubMed ID: 22064379)
1. Conversion of a murine monoclonal antibody A13 targeting epidermal growth factor receptor to a human monoclonal antibody by guided selection.
Chang KH; Kim MS; Hong GW; Shin YN; Kim SH
Exp Mol Med; 2012 Jan; 44(1):52-9. PubMed ID: 22064379
[TBL] [Abstract][Full Text] [Related]
2. A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab.
Hong KW; Kim CG; Lee SH; Chang KH; Shin YW; Ryoo KH; Kim SH; Kim YS
J Biotechnol; 2010 Jan; 145(1):84-91. PubMed ID: 19828124
[TBL] [Abstract][Full Text] [Related]
3. Affinity Maturation of an Epidermal Growth Factor Receptor Targeting Human Monoclonal Antibody ER414 by CDR Mutation.
Chang KH; Kim MS; Hong GW; Seo MS; Shin YN; Kim SH
Immune Netw; 2012 Aug; 12(4):155-64. PubMed ID: 23091439
[TBL] [Abstract][Full Text] [Related]
4. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
[TBL] [Abstract][Full Text] [Related]
5. Effective therapeutic approach for head and neck cancer by an engineered minibody targeting the EGFR receptor.
Kim YP; Park D; Kim JJ; Chi WJ; Lee SH; Lee SY; Kim S; Chung JM; Jeon J; Lee BD; Shin JH; Lee YI; Cho H; Lee JM; Kang HC
PLoS One; 2014; 9(12):e113442. PubMed ID: 25438047
[TBL] [Abstract][Full Text] [Related]
6. Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro.
Yi CH; Ruan CP; Wang H; Xu XY; Zhao YP; Fang M; Ji J; Gu X; Gao CF
Acta Pharmacol Sin; 2014 Nov; 35(11):1439-46. PubMed ID: 25263334
[TBL] [Abstract][Full Text] [Related]
7. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.
Johns TG; Stockert E; Ritter G; Jungbluth AA; Huang HJ; Cavenee WK; Smyth FE; Hall CM; Watson N; Nice EC; Gullick WJ; Old LJ; Burgess AW; Scott AM
Int J Cancer; 2002 Mar; 98(3):398-408. PubMed ID: 11920591
[TBL] [Abstract][Full Text] [Related]
8. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.
Johns TG; Adams TE; Cochran JR; Hall NE; Hoyne PA; Olsen MJ; Kim YS; Rothacker J; Nice EC; Walker F; Ritter G; Jungbluth AA; Old LJ; Ward CW; Burgess AW; Wittrup KD; Scott AM
J Biol Chem; 2004 Jul; 279(29):30375-84. PubMed ID: 15075331
[TBL] [Abstract][Full Text] [Related]
9. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor efficacy of an anti-epidermal-growth-factor-receptor monoclonal antibody and its F(ab')2 fragment against high- and low-EGFR-expressing carcinomas in nude mice.
Tosi E; Valota O; Negri DR; Adobati E; Mazzoni A; Meazza R; Ferrini S; Colnaghi MI; Canevari S
Int J Cancer; 1995 Sep; 62(5):643-50. PubMed ID: 7665239
[TBL] [Abstract][Full Text] [Related]
11. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling.
Boersma YL; Chao G; Steiner D; Wittrup KD; Plückthun A
J Biol Chem; 2011 Dec; 286(48):41273-41285. PubMed ID: 21979953
[TBL] [Abstract][Full Text] [Related]
12. Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.
Donaldson JM; Kari C; Fragoso RC; Rodeck U; Williams JC
Cancer Biol Ther; 2009 Nov; 8(22):2147-52. PubMed ID: 19783899
[TBL] [Abstract][Full Text] [Related]
13. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.
Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG
Crit Rev Oncol Hematol; 2001 Apr; 38(1):17-23. PubMed ID: 11255078
[TBL] [Abstract][Full Text] [Related]
14. Affinity maturation and fine functional mapping of an antibody fragment against a novel neutralizing epitope on human vascular endothelial growth factor.
Lamdan H; Gavilondo JV; Muñoz Y; Pupo A; Huerta V; Musacchio A; Pérez L; Ayala M; Rojas G; Balint RF; Larrick JW
Mol Biosyst; 2013 Aug; 9(8):2097-106. PubMed ID: 23702826
[TBL] [Abstract][Full Text] [Related]
15. Development of humanized scFv antibody fragment(s) that targets and blocks specific HLA alleles linked to myasthenia gravis.
Ayyar BV; Atassi MZ
Appl Microbiol Biotechnol; 2017 Nov; 101(22):8165-8179. PubMed ID: 29034433
[TBL] [Abstract][Full Text] [Related]
16. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.
Müller N; Hartmann C; Genssler S; Koch J; Kinner A; Grez M; Wels WS
Int J Cancer; 2014 Jun; 134(11):2547-59. PubMed ID: 24243620
[TBL] [Abstract][Full Text] [Related]
17. Generation of humanized single-chain fragment variable immunotherapeutic against EGFR variant III using baculovirus expression system and in vitro validation.
Xavier S; Gopi Mohan C; Nair S; Menon KN; Vijayachandran LS
Int J Biol Macromol; 2019 Mar; 124():17-24. PubMed ID: 30471391
[TBL] [Abstract][Full Text] [Related]
18. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies.
Zhou Y; Goenaga AL; Harms BD; Zou H; Lou J; Conrad F; Adams GP; Schoeberl B; Nielsen UB; Marks JD
Mol Cancer Ther; 2012 Jul; 11(7):1467-76. PubMed ID: 22564724
[TBL] [Abstract][Full Text] [Related]
19. Design, expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor (EGFR).
Akbari B; Farajnia S; Zarghami N; Mahdieh N; Rahmati M; Khosroshahi SA; Rahbarnia L
Protein Expr Purif; 2016 Nov; 127():8-15. PubMed ID: 27298212
[TBL] [Abstract][Full Text] [Related]
20. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy.
Bleeker WK; Lammerts van Bueren JJ; van Ojik HH; Gerritsen AF; Pluyter M; Houtkamp M; Halk E; Goldstein J; Schuurman J; van Dijk MA; van de Winkel JG; Parren PW
J Immunol; 2004 Oct; 173(7):4699-707. PubMed ID: 15383606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]